Pfizer (NY:PFE)

27.80 -0.32 (-1.14%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Most active S&P500 stocks in Monday's session ↗

August 10, 2026

Via Chartmill

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner? ↗

August 10, 2026

The stock's 6.4% yield is attractive, but it comes with risk.

Via The Motley Fool

Global Precision Medicine Market: Size, Trends, Drivers, and Forecast 2026-2033 ↗

August 10, 2026

The Precision Medicine industry is rapidly transforming healthcare delivery by enabling personalized treatment strategies tailored to genetic, environmenta

Via Talk Markets

Topics Artificial Intelligence

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗

August 07, 2026

Berobenatide is one of the keys to Pfizer's future.

Via The Motley Fool

Most active S&P500 stocks in Friday's session ↗

August 07, 2026

Via Chartmill

Pfizer (NYSE:PFE) Beats Q2 Expectations and Raises 2026 Revenue Guidance ↗

August 04, 2026

Via Chartmill

Curious about the most active S&P500 stocks in today's session? ↗

August 06, 2026

Via Chartmill

Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations

August 06, 2026

Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The comp...

Via StockStory

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

August 06, 2026

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion....

Via StockStory

3 Beaten-Down Stocks to Hold for the Next 10 Years ↗

August 05, 2026

Don't let their recent poor performances chase you away.

Via The Motley Fool

Topics Intellectual Property

Pfizer Q2 Earnings Call Highlights ↗

August 05, 2026

Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue...

Via MarketBeat

Topics Earnings Intellectual Property

S&P 500 Prints Fresh Record As Chips Rip And Hormuz Talks Crack The Oil Trade ↗

August 05, 2026

Via Chartmill

Topics Stocks

PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands

August 05, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15...

Via StockStory

Topics Artificial Intelligence

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

August 04, 2026

Via Chartmill

Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss ↗

August 04, 2026

Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.

Via Benzinga

BioNTech Q2 Earnings Call Highlights ↗

August 04, 2026

BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year...

Via MarketBeat

Topics Earnings

Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings ↗

August 04, 2026

Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations. Oil down 4.2%, gold up 0.8%, European markets higher.

Via Benzinga

Topics Stocks

Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat ↗

August 04, 2026

Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.

Via Investor's Business Daily

Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue

August 04, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15...

Via StockStory

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

August 04, 2026

From Pfizer Inc.

Via Business Wire

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday ↗

August 04, 2026

Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued.

Via Benzinga

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

August 04, 2026

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.

Via Benzinga

SpaceX Could Swing $204 Billion After Earnings ↗

August 03, 2026

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Via Benzinga

Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield? ↗

August 03, 2026

The stock's yield is more than six times the S&P 500 average.

Via The Motley Fool

Topics Stocks

Pfizer (PFE) Q2 Earnings: What To Expect

August 02, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Pfizer beat analysts’ rev...

Via StockStory

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗

August 01, 2026

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Via The Motley Fool

Topics Intellectual Property

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock? ↗

July 31, 2026

There is more to this stock than meets the eye.

Via The Motley Fool

Topics Intellectual Property

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...

Via MarketBeat

Topics ETFs Earnings

Regency Centers Q2 Earnings Call Highlights ↗

July 30, 2026

Regency Centers (NASDAQ:REG) reported second-quarter operating momentum marked by higher occupancy, rent growth and an expanded development pipeline, prompting the grocery-anchored shopping center...

Via MarketBeat

Topics ETFs Earnings

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials ↗

July 30, 2026

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.